Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Teva acquires Sicor for $3.3bn in cash and stock

Executive Summary

Teva Pharmaceutical Industries will acquire Sicor (generic injectable drugs) and merge it with one of its subsidiaries. Teva is paying $16.50 in cash and 0.19 of a Teva ADR (currently valued at $10.90 each) for each Sicor common share, for a total of $3.3bn.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Stock
    • Payment Includes Cash
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register